

# Fiera Atlas Global Companies Fund – Class A

## OBJECTIVE

The Fund seeks to deliver a compound rate of return greater than 10% p.a., after fees and costs, with a lower risk of capital loss than broader equity markets, over the long term (typically 5 to 7 years).

## HIGHLIGHTS

- 25 – 35 holdings
- High quality growth at a reasonable price
- Low turnover
- Fundamental bottom-up process

<b>ARSN</b>	627 620 320	<b>APIR</b>	AMP7497AU
<b>BENCHMARK</b>	Unaware	<b>INCEPTION DATE</b>	31 August 2018
<b>MANAGEMENT FEE</b>	0.9500% p.a.	<b>FUND SIZE</b>	\$31.6m
<b>BUY / SELL SPREAD</b>	+0.30% / -0.30%	<b>EXIT PRICE</b>	\$1.4104

## Net performance (%)

	1 month	3 months	1 year	2 years p.a.	3 years p.a.	5 years p.a.	Since inception p.a.
<b>Fund</b>	<b>-2.68</b>	<b>-17.49</b>	<b>6.87</b>	<b>16.64</b>	<b>15.63</b>	<b>n/a</b>	<b>13.82</b>
MSCI ACWI NR <sup>1</sup>	-1.28	-8.37	8.81	16.27	11.66	11.99	9.69
Active	-1.40	-9.12	-1.94	0.37	3.97	n/a	4.13
Composite <sup>2</sup>	--	--	--	--	--	20.07	20.07


<sup>1</sup>MSCI ACWI NR Index is referenced for comparison purposes only. The since inception return is from the Fund's inception date.

<sup>2</sup>To provide a longer-term view of the Fund, performance from 1 April 2017 to 31 August 2018 for the Fiera Atlas Global Companies Composite – Class A reflects the returns of Class C, net of fees applicable to Class A. Class C was inception 30 March 2017. Performance from 1 September 2018 to-date reflects the actual net returns of the Fiera Atlas Global Companies Fund – Class A.


## Top 5 holdings

Stocks	Sector	Country
Synopsys	Information Technology	United States
Intuitive Surgical	Health Care	United States
Visa	Information Technology	United States
Gartner	Information Technology	United States
Zoetis	Health Care	United States

## Regional asset allocation (%)



## Sector asset allocation (%)



Past performance is not indicative of future performance. Net performance figures are calculated using exit prices, net of fees and reflect the annual reinvestment of distribution. Returns are rounded to two decimal places. Slight variations to actual calculations may occur.

## CONTACT DETAILS

T.1800 034 402 | E. Client.Services@ironbarkam.com | W. www.ironbarkam.com

### Top 5 quarterly contributors and detractors

Contributing stocks	Sector	Detracting stocks	Sector
Aspen Technology	Information Technology	Sartorius	Health Care
West Pharmaceutical Services	Health Care	Zoetis	Health Care
Visa	Information Technology	Autodesk	Information Technology
Amazon	Consumer Discretionary	Intuitive Surgical	Health Care
Adyen	Information Technology	Wuxi Biologics	Health Care

### Quarterly commentary

The Fund's commentary for the quarter ending 31 March 2022 is unavailable at this time. The report will be updated on the website with this information as soon as it becomes available. We apologise for any inconvenience caused. If you have any questions, please contact your Key Account Manager or Ironbark on 1800 034 402.

Issued by Ironbark Asset Management (Fund Services) Limited ABN 63 116 232 154 AFSL 298626 ('Ironbark'). Ironbark is the responsible entity for the Fund(s) referred to in this document. The relevant target market determination (TMD) and offer document for the Fund(s) is available from [www.ironbarkam.com/our-funds/](http://www.ironbarkam.com/our-funds/) or by calling Ironbark on 1800 034 402. This document contains general information only and is not intended to represent specific investment or professional advice. The information does not take into account an individual's personal financial circumstances, objectives or needs. Before making an investment decision, you should consider obtaining professional investment advice that takes into account your personal circumstances and should read the current TMD and offer document before making an investment decision to acquire or to continue to hold units in the Fund. Ironbark and its representatives believe that the information in this document is correct at the time of compilation, but no warranty of accuracy or reliability is given and no responsibility arising in any other way for errors or omissions (including responsibility to any person due to negligence) is accepted by Ironbark. To the extent permitted by law, Ironbark, its employees, consultants, advisers, officers and representatives are not liable for any loss or damage arising as a result of reliance placed on the contents of this document. While any forecasts, estimates and opinions in this material are made on a reasonable basis, actual future results and operations may differ materially from the forecasts, estimates and opinions set out in this material. No guarantee as to the repayment of capital or the performance of any product or rate of return referred to in this material is made by Ironbark. Past performance is not a reliable indicator of future performance. All currency references are shown in Australian dollars unless stated otherwise. All indices are copyrighted by and proprietary to the issuer of the index. Any investment is subject to investment risk, including delays on the payment of withdrawal proceeds and the loss of income or the principal invested. This document is not intended for distribution to, or use by, any person or entity in any jurisdiction or country where such distribution or use would be contrary to local law or regulation. No part of this material may be reproduced or distributed in any manner without the prior written permission of Ironbark.

#### CONTACT DETAILS

T.1800 034 402 | E. Client.Services@ironbarkam.com | W. www.ironbarkam.com